Since 2023, the pharmaceutical industry has intensified its commitment to artificial intelligence (AI) to revolutionize drug discovery. The world’s 10 largest pharma companies are actively collaborating with AI-specialized startups while developing their own AI-powered discovery engines. This dual strategic movement reflects a unanimous awareness: AI can transform a costly and lengthy process into a faster, less risky, and more targeted approach.
A strategic convergence: partnerships and acquisitions
Major pharmaceutical companies are not merely collaborating with startups: they are investing heavily in targeted acquisitions. The most striking example is Takeda, which spent $4 billion in 2023 to acquire the plaque psoriasis treatment developed by Nimbus Therapeutics. This type of acquisition illustrates the growing interest of pharmaceutical giants in integrating AI solutions into their portfolios.
Beyond these acquisitions, the rise of internal initiatives marks a new stage. Nine of the ten largest laboratories have launched their own AI-assisted discovery programs, thereby strengthening their capacity to innovate internally. This strategy allows them to diversify their approaches and secure access to a key technology in an ultra-competitive sector.
Why is AI so appealing to the pharmaceutical industry?
Developing a drug represents a colossal investment, costing an average of $1.3 billion per product. AI is emerging as a cost-reduction solution while accelerating time-to-market. It is involved in four main areas:
- Target identification: AI offers the ability to identify biological targets linked to a disease, often proteins, with increased precision.
- Drug repositioning: AI redefines the use of existing drugs for new indications, maximizing already available resources.
- Drug-target interactions: Through prediction of interactions between compounds and biological targets, AI facilitates the selection of the most promising molecules.
- Generative chemistry: AI proposes new chemical compounds, paving the way for entirely novel solutions.
These advances explain why AI is now at the heart of a genuine innovation race, which CB Insights describes as an “arms race” in its sector analyses.
M&A activity in full swing
Mergers and acquisitions in AI applied to drug discovery have exploded. Since 2023, eight of the ten largest transactions in this sector have taken place. This dynamic is supported by two main factors: the growing maturity of technologies and the urgency felt by major players to acquire these innovations.
Numerous challenges remain
Despite the promises, AI-designed drugs must still pass the critical stages of clinical trials. The recent failures of Exscientia and Benevolent AI, which discontinued trials in 2023, remind us that the path to commercialization is fraught with obstacles. However, other players such as Nimbus Therapeutics and Insilico Medicine are progressing through clinical phases, raising hopes regarding the validation of AI capabilities.
If late-stage clinical trials succeed, this could mark a turning point for AI adoption. Conversely, repeated failures could dampen the enthusiasm of investors and companies.
Growing interest in AI startups
The AI-specialized startup sector is also attracting attention, not only for their technological capabilities but also for their potential to disrupt. With players like Insilico Medicine or Atomwise, innovations are multiplying, particularly in the design of generative platforms that accelerate the discovery and optimization phases of molecules.
The flip side: ethical questions and technological limitations
The integration of AI raises ethical and technical concerns. The massive data used by these technologies raise questions about privacy and security. The increased reliance on AI in decision-making processes also sparks debates about human responsibility in a field as sensitive as healthcare.
Recent clinical failures show that AI, while impressive, is not infallible. This highlights the importance of rigorous human oversight and a balance between technological innovation and traditional scientific validation.
Sources CB Insights
